Consider quality of life, comorbidities in hidradenitis suppurativa

Expert shares tips to optimize management of this challenging condition.

Address root causes to manage NASH

Treat underlying factors such as obesity and diabetes to reduce risk of liver disease progression.

DDNA19: Cardiac Complications in Liver Disease Patients

Dr. Marc Klapholz explains the latest developments in portopulmonary arterial hypertension, hepatopulmonary syndrome, and cirrhotic cardiomyopathy.

CARDIA: Smoke-free policies linked to lower blood pressure

Every story needs a teaser. Must differ from the headline. Meeting stories need a dateline. 150 characters or fewer.

Invasive strategy increased bleeding risk in frail older AMI patients

Registry analysis suggests frailty in an AMI patient calls for personalized decision making.

HCV antibodies linked to poorer cardiac outcomes in ACHD patients

Adults with congenital heart disease and HCV antibody positivity had significantly worse cardiac outcomes.

Children with poor cardiorespiratory fitness have a higher risk of type 2 diabetes and cardiovascular disease

Risk for type 2 diabetes mellitus and cardiovascular disease in adulthood can be calculated by measuring cardiorespiratory fitness in childhood.

Quality of life with PAD follows function, not clinical markers

Patients with symptomatic PAD rate their health-related quality of life based on functional capabilities, not markers of disease severity or comorbidities.

Psoriasis duration reflects cardiovascular event risk

For every year of psoriasis, a patient’s risk of a major cardiovascular event climbs an additional 1%.

Tune in to cardiovascular risk in psoriasis

Treatment of psoriasis also improves markers of vascular inflammation.

Pages